1

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

ezxsxnjhdqrm
BackgroundIn breast cancers. only a minority of patients fully benefit from the different chemotherapy regimens currently in use. Identification of markers that could predict the response to a particular regimen would thus be critically important for patient care. In cell lines or animal models. https://www.shopwildwestes.shop/product-category/jewlery/
Report this page

Comments

    HTML is allowed

Who Upvoted this Story